

Rishi S Kotecha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8060389/publications.pdf>

Version: 2024-02-01

64
papers

1,133
citations

471371

17
h-index

454834

30
g-index

67
all docs

67
docs citations

67
times ranked

1897
citing authors

#	ARTICLE	IF	CITATIONS
1	Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. <i>Haematologica</i> , 2022, 107, 635-643.	1.7	16
2	COVID-19 vaccination for children with cancer. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29340.	0.8	5
3	Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol. <i>European Journal of Cancer</i> , 2022, 160, 72-79.	1.3	11
4	COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children's Haematology/Oncology Group consensus statement. <i>Medical Journal of Australia</i> , 2022, 216, 312-319.	0.8	3
5	Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1508-1524.	1.3	7
6	The Bone Marrow Microenvironment in B-Cell Development and Malignancy. <i>Cancers</i> , 2022, 14, 2089.	1.7	10
7	Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease. <i>British Journal of Haematology</i> , 2022, 198, 887-892.	1.2	6
8	Are outcomes for childhood leukaemia in Australia influenced by geographical remoteness and Indigenous race?. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28945.	0.8	3
9	Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28922.	0.8	16
10	Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 652-662.	0.8	41
11	<i>RUNX2</i> regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
12	Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children's Oncology Group (ANZCHOG) Study. <i>Frontiers in Oncology</i> , 2021, 11, 660172.	1.3	1
13	Preclinical Evaluation of Carfilzomib for Infant <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 631594.	1.3	12
14	Case Report: Long-Term Survival of a Pediatric Patient With an Intra-Abdominal Undifferentiated Carcinoma of Unknown Primary. <i>Frontiers in Oncology</i> , 2021, 11, 590913.	1.3	0
15	Therapeutic Targeting of the Leukaemia Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6888.	1.8	16
16	Viridans Group Streptococci in Pediatric Leukemia and Stem Cell Transplant: Review of a Risk-stratified Guideline for Empiric Vancomycin in Febrile Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 832-834.	1.1	3
17	Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29275.	0.8	10
18	Defining the fetal origin of MLL-AF4 infant leukemia highlights specific fatty acid requirements. <i>Cell Reports</i> , 2021, 37, 109900.	2.9	10

#	ARTICLE	IF	CITATIONS
19	Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Blood</i> , 2021, 138, 2383-2383.	0.6	0
20	Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 779859.	1.3	3
21	Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 773-779.	1.3	13
22	Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignancies. <i>Pediatric Transplantation</i> , 2020, 24, e13602.	0.5	6
23	Immunogenicity of the inactivated influenza vaccine in children who have undergone autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 1829-1831.	1.3	1
24	The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution. <i>Scientific Reports</i> , 2020, 10, 19173.	1.6	16
25	Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome. <i>Leukemia</i> , 2020, 34, 1984-1999.	3.3	34
26	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. <i>Blood</i> , 2020, 135, 1685-1695.	0.6	28
27	Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2898-2902.	3.3	4
28	Challenges posed by COVID-19 to children with cancer. <i>Lancet Oncology</i> , The, 2020, 21, e235.	5.1	72
29	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3307-3318.	3.2	28
30	Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2020, 1, 274-289.	2.6	21
31	Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children. <i>Cancers</i> , 2020, 12, 1285.	1.7	5
32	Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003-2013. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27915.	0.8	34
33	DISSECTION OF THE PRE-B LEUKAEMIA BONE MARROW MICROENVIRONMENT. <i>Experimental Hematology</i> , 2019, 76, S62.	0.2	0
34	Romidepsin enhances the efficacy of cytarabine <i>in vivo</i> , revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, e300-e303.	1.7	10
35	Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. <i>Blood Advances</i> , 2019, 3, 4291-4297.	2.5	17
36	A Novel Missense Mutation Affecting the N-terminal Domain of SAP Protein in X-linked Lymphoproliferative Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e550-e551.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Vaccine-preventable disease following allogeneic haematopoietic stem cell transplant in Western Australia. <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 343-348.	0.4	6
38	Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27564.	0.8	31
39	Targeting the bone marrow microenvironment: a novel therapeutic strategy for pre-B acute lymphoblastic leukemia. <i>Oncotarget</i> , 2019, 10, 1756-1757.	0.8	4
40	Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27065.	0.8	4
41	New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment. <i>Leukemia</i> , 2018, 32, 2326-2338.	3.3	32
42	Regular exercise improves the well-being of parents of children with cancer. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26668.	0.8	9
43	High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission. <i>Cancer</i> , 2017, 123, 2781-2782.	2.0	1
44	Rare pattern of relapse to the pancreas and bilateral extraocular muscles in paediatric alveolar rhabdomyosarcoma. <i>Journal of Paediatrics and Child Health</i> , 2017, 53, 419-421.	0.4	0
45	Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. <i>Supportive Care in Cancer</i> , 2017, 25, 3289-3290.	1.0	1
46	Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. <i>Cancer</i> , 2017, 123, 4215-4223.	2.0	23
47	Molecular-genetic profiling and high-throughput <i>in vitro</i> drug screening in NUT midline carcinoma—an aggressive and fatal disease. <i>Oncotarget</i> , 2017, 8, 112313-112329.	0.8	29
48	Successful Treatment of Congenital Erythroleukemia With Low-Dose Cytosine Arabinoside. <i>Pediatric Blood and Cancer</i> , 2016, 63, 566-567.	0.8	3
49	Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. <i>Cancer Medicine</i> , 2016, 5, 285-293.	1.3	19
50	Increased Body Mass Index during Therapy for Childhood Acute Lymphoblastic Leukemia: A Significant and Underestimated Complication. <i>International Journal of Pediatrics (United Kingdom)</i> , 2015, 2015, 1-10.	0.2	7
51	Rare childhood cancers—an increasing entity requiring the need for global consensus and collaboration. <i>Cancer Medicine</i> , 2015, 4, 819-824.	1.3	16
52	Hepatic Sinusoidal Obstruction Syndrome During Chemotherapy for Childhood Medulloblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 76-80.	0.3	18
53	Acute Onset of Pustules at the Site of Tape Placement in an Immunocompromised Infant with Acute Myeloid Leukemia. <i>Pediatric Dermatology</i> , 2014, 31, 609-610.	0.5	7
54	Childhood craniopharyngioma: 20-year institutional experience in Western Australia. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, 403-408.	0.4	22

#	ARTICLE	IF	CITATIONS
55	Morbidity in survivors of child and adolescent meningioma. <i>Cancer</i> , 2013, 119, 4350-4357.	2.0	19
56	Efficacy of acute myeloid leukemia therapy without stem-cell transplantation in a child with blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2013, 98, e30-e31.	1.7	5
57	Molecular characterization of identical, novel MLL-EPS15 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. <i>Haematologica</i> , 2012, 97, 1447-1450.	1.7	3
58	Chemotherapy Increases Amenability of Surgical Resection in Congenital Glioblastoma. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 538-544.	0.3	15
59	Pre-natal, clonal origin of t(1;11)(p32;q23) acute lymphoblastic leukemia in monozygotic twins. <i>Leukemia Research</i> , 2012, 36, 46-50.	0.4	5
60	Meningiomas in children and adolescents: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2011, 12, 1229-1239.	5.1	138
61	Pediatric meningioma: current approaches and future direction. <i>Journal of Neuro-Oncology</i> , 2011, 104, 1-10.	1.4	68
62	Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). <i>Pediatric Blood and Cancer</i> , 2010, 54, 934-940.	0.8	53
63	The Fremantle lead study part 2. <i>Journal of Paediatrics and Child Health</i> , 2008, 44, 722-726.	0.4	9
64	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	6